Creative Biolabs to Showcase Tumoroid-on-a-Chip Technology in Upcoming Webinar
Creative Biolabs is set to host a webinar on tumoroid-on-a-chip technology, highlighting its potential to revolutionize cancer research and drug development by offering more physiologically relevant conditions for preclinical testing.
Creative Biolabs announced an upcoming webinar on August 22, 2025, focusing on the tumoroid-on-a-chip platform, a microfluidic-based 3D tumor model designed to enhance preclinical testing accuracy. The webinar, presented by Dr. Mohsen Akbari from the University of Victoria, aims to explore the technology's role in advancing cancer research and drug development.
The tumoroid-on-a-chip platform represents a significant leap forward from traditional 2D cultures by incorporating key structural and cellular features of solid tumors, thus providing a more representative in vitro environment. This innovation is crucial for the accurate assessment of drug responses and has the potential to significantly narrow the gap between laboratory research and clinical applications.
Key topics of the webinar include the evolution of tumor chips, strategies for incorporating cellular heterogeneity and ECM complexity, and the application of these systems in immunotherapy screening and preclinical drug testing. Dr. Akbari's expertise in microengineering and biomaterials, along with his contributions to over 140 peer-reviewed articles, positions him as a leading voice in this field.
Creative Biolabs supports oncology research through its comprehensive portfolio of 3D tumor modeling platforms, including Ex Vivo Tissue Models and Organ-on-a-Chip Models, which are instrumental in evaluating drug responses in conditions that closely mimic the in vivo tumor microenvironment.